United States Patent 3,839,573: Scope, Claims, and US Landscape for an Imidazole Antifungal
What does US Drug Patent 3,839,573 claim in enforceable terms?
US Patent 3,839,573 (issued Oct. 6, 1975) claims a composition for antifungal treatment in humans and animals. The claim is written as a product-by-formula plus formulation requirement.
Independent claim (as provided)
Claim 1 (composition claim) recites:
- Purpose/utility: “useful for administration to humans and animals”
- Active ingredient (core limitation): an amount of a compound of the formula
1-((X"-phenyl)-C(C6H5)2-)imidazole
where X" is m-methyl, or a pharmaceutically acceptable non-toxic salt thereof
- Efficacy limitation: “sufficient to be therapeutically effective against fungi pathogenic to humans and animals”
- Formulation limitation: in combination with a pharmaceutically acceptable non-toxic inert diluent or carrier
How the claim is structured (practical scope)
The enforceable scope is defined by four lock-in elements:
- Element A: compound identity by formula with X" = m-methyl
The active ingredient must match the specific substituted imidazole structure with meta-methyl on the specified phenyl ring.
- Element B: salt coverage
The claim covers salts of the specified compound, provided they are “pharmaceutically acceptable” and “non-toxic.”
- Element C: intended administration (humans and animals)
This limits practical use to both contexts, but composition coverage generally persists regardless of who administers it.
- Element D: formulation carrier/diluent
The claim requires an antifungal composition that includes a pharmaceutically acceptable inert diluent or carrier. This is typically satisfied by standard formulation excipients.
Scope implications
- Narrow active-ingredient scope, broad formulation scope. The hard boundary is the exact formula with m-methyl; the excipient/diluent language is broad.
- Salt strategy matters. If a competitor uses a different counterion, the question becomes whether it falls within “pharmaceutically acceptable non-toxic” salts of the same imidazole.
- Therapeutic effect language does not usually narrow composition identity. Courts generally treat “therapeutically effective” as a functional requirement that constrains dosage/formulation amount, not the chemical structure.
What exact compound family is the claim targeting?
The claim targets a substituted imidazole with a triarylmethyl-like substitution pattern as written:
- Core scaffold: imidazole
- Substitution: 1-((X"-phenyl)-C(C6H5)2-)imidazole
- X" substituent: m-methyl (meta-methyl)
Claim-meaning in infringement terms
A product infringes if it contains, in sufficient amount, a compound that falls within the described formula with X" = m-methyl, or its acceptable salt, formulated in a pharmaceutically acceptable carrier.
The claim, as written, does not cover:
- other positional isomers (o-, p- methyl) unless they fall literally within “X" is m-methyl”
- other X substituents
- different antifungal actives even if chemically related
It does cover:
- the specified m-methyl compound(s)
- salts of that compound(s) (as characterized by pharmaceutically acceptable/non-toxic standard)
How would this claim read on common antifungal product designs?
1) Finished dosage forms
The carrier/diluent requirement reads onto:
- tablets, capsules, suspensions, syrups
- creams, ointments, gels (topical carriers are “diluents or carriers”)
- injectable or veterinary formulations if otherwise compatible
Infringement analysis would turn on:
- presence/amount of the specified active (or salt)
- whether the “non-toxic” qualifier is met for the specific salt
2) Salt-only changes
If a competitor changes the salt counterion:
- they avoid literal claim coverage only if the salt is not “pharmaceutically acceptable non-toxic”
- otherwise, the salt is still inside the claim language
In practice, most pharmaceutically used salts are likely to be “acceptable” and “non-toxic” in a drug-formulation sense.
3) Active-ingredient engineering
Avoidance strategies must typically change:
- the substitution pattern such that X" is no longer m-methyl, or
- the core structure such that it no longer matches the claimed formula
Changing excipients and dosage form rarely escapes a composition-by-active claim.
Where does US 3,839,573 sit in the broader US antifungal patent landscape?
US 3,839,573 is from the mid-1970s and is drafted as a chemical composition claim, not a method-of-treatment claim. In this era, US antifungal portfolios often split into:
- Chemical entity patents (formula scope)
- Composition/formulation patents (carriers, dosage forms)
- Uses/methods (therapeutic regimens)
- Salt and polymorph follow-ons (later generation breadth controls)
Landscape pattern consistent with the claim
- This patent’s enforceable anchor is the exact substituted imidazole identity (X" = m-methyl) rather than a broad class of imidazoles.
- Its formulation claim language implies enforceability against generic “same active, different excipient” products, at least until the patent term expires (and subject to prosecution history/claim construction).
Practical competitive map (US market posture)
For a generic or competitor entering with:
- the same active (m-methyl substituted compound)
the patent blocks straightforward product launches unless a clearance route exists (e.g., non-infringement by different substitution, invalidity, or expiration).
- a different positional isomer or different X-substituent
the claim offers a direct literal avoidance path because X" is specified as m-methyl.
What scope is missing from Claim 1 (and what that means for enforcement)?
Because Claim 1 is limited to a composition and a specific formula with X" = m-methyl, enforcement typically focuses on:
- composition containing the specified compound identity
- salt equivalents that qualify as pharmaceutically acceptable/non-toxic
- presence in a carrier
Scope gaps (as drafted):
- It does not explicitly cover methods of treatment beyond “useful for administration.”
- It does not specify particular dosage levels, routes, or indications. A composition could still be within the claim if it is formulated and intended to be therapeutically effective against pathogenic fungi.
This means competitors may still face exposure if they market the same active composition for fungal infections, but the claim’s breadth remains tethered to the active identity.
Key claim-construction pressure points
These issues typically drive the outcome in infringement and validity disputes:
- Parsing of the chemical formula
Claim language uses nested functional descriptors. Construction must map to a concrete structure consistent with “1-((X"-phenyl)-C(-C6H5)2-)imidazole” and the stated constraint X" = m-methyl.
- Definition of “X"-phenyl” and where “m-methyl” sits
The claim explicitly states X" is m-methyl, but the mapping of that substituent to a specific phenyl ring is essential.
- Salt language
“Pharmaceutically acceptable non-toxic salt thereof” can become a dispute over whether a given salt meets acceptance/non-toxicity standards.
- Carrier/diluent
Most standard pharmaceutical carriers qualify. The dispute tends to revert to active identity rather than excipient composition.
Patent landscape deliverables for business decisions
Freedom-to-operate lens
- Highest risk: launching any US product containing the m-methyl substituted imidazole of the stated formula (and qualifying salts) in a pharmaceutically acceptable carrier for antifungal use in humans or animals.
- Lower risk: products using closely related positional isomers or other substituents where X" is not m-methyl.
- Salt strategy: changing counterions alone is unlikely to avoid the claim if the salt is standard pharmaceutically acceptable/non-toxic.
Competitive intelligence lens
- The claim targets a specific substitution pattern; competitors can map their internal chemistry to “X is m-methyl” vs “X is not m-methyl” as a first-pass screen.
- If a competitor has an ANDA/abbreviated product dossier with the same active, the composition claim is a direct obstacle unless expiration/invalidity is available.
Key Takeaways
- US 3,839,573 Claim 1 is a composition claim for antifungal treatment in humans and animals with an active defined by a specific imidazole formula requiring X" = m-methyl.
- The claim’s enforceable boundary is active identity; the carrier/diluent language is broad, so changing formulation excipients alone does not avoid infringement.
- Salt coverage can extend protection to pharmaceutically acceptable non-toxic salts of the same active.
- Competitive entry hinges on whether the competitor’s active ingredient matches the m-methyl substituted structure; positional or substituent changes are the main literal avoidance lever.
FAQs
1) Does the claim cover topical antifungals?
Yes, if the product contains the claimed m-methyl imidazole (or acceptable non-toxic salt) in a pharmaceutically acceptable inert diluent or carrier and is formulated for antifungal use.
2) Can a competitor avoid infringement by changing the counterion (salt)?
Only if the new salt is not “pharmaceutically acceptable” and/or is not “non-toxic” as characterized for pharmaceutical use; standard pharmaceutically acceptable salts often remain within the claim.
3) Does the claim cover other X" substituents (e.g., p-methyl or o-methyl)?
No, the claim language specifies X" is m-methyl. Other substituent patterns fall outside literal scope unless they still meet the stated limitation.
4) Is the claim limited to a specific dosage form or dosing regimen?
Claim 1 requires only an antifungal composition in a carrier with therapeutically effective amount; it does not specify a particular route, regimen, or dosage form.
5) Is this a method-of-use patent or a composition patent?
It is drafted primarily as a composition claim. “Useful for administration” supports intended use but the claim’s structural limitations focus on the active compound and formulation.
References (APA)
[1] United States Patent 3,839,573. (1975). Antifungal composition.
